Inhaled drugs by device type (with current FDA approval for patients with COPD)
| Drugs available | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| SAMA | SABA | SAMA/ SABA | LAMA | LABA | LAMA/ LABA | ICS/LABA | ICS/ LAMA/ LABA | ||
| HFA MDIs | IPR (Atrovent)a | ALB (ProAir HFA,b Ventolin HFA,c Proventil HFAd) | GLY/FOR (Bevespi Aero- sphere)f | FP/SAL (Advair)cBUD/FOR Inhalation Aerosol (Symbicort)f | |||||
| LLB (Xopenex HFAe) | |||||||||
| DPIs | Aerolizerg | FOR (Foradil) | |||||||
| Diskusc | SAL (Serevent) | FP/SAL (Advair) | |||||||
| Elliptac | UME (Incruse) | UME/VIL (Anoro) | FF/VIL (Breo) | FF/UME/ VIL (Trelegy) | |||||
| HandiHalera | TIO (Spiriva) | ||||||||
| Neohalerg | GLY (Seebri) | IND (Arcapta) | GLY/IND (Utibron) | ||||||
| Pressairf | ACL (Tudorza) | ||||||||
| SMIs | Respimata | IPR/ALB (Combi- vent) | TIO (Spiriva) | OLO (Striverdi) | TIO/OLO (Stiolto) | ||||
| Nebulizers* | Breath- enhanced jet (eg, PARI LC Plus ) h | IPR (Atrovent)a | ALB (Proventild, Ventolinc) LLB (Xopenexe) | IPR/ALB (DuoNeb)l | ARF (Brovana)eFOR (Performo- mist)l | ||||
| Breath-actuatedjet (eg, AeroEclipse II BANi) | |||||||||
| Ultrasonic (eg, UltraNebj) | |||||||||
| Vibrating mesh† (eg, AKITA APIXNEBk) | |||||||||
Abbreviations: ACL, aclidinium; ALB, albuterol; ARF, arformoterol; BAN, breath actuated nebulizer; BUD, budesonide; COPD, chronic obstructive pulmonary disease; DPI, dry powder inhaler; FDA, US Food and Drug Administration; FF, fluticasone furoate; FOR, formoterol; FP, fluticasone propionate; GLY, glycopyrrolate; HFA, hydrofluoroalkane; ICS, inhaled corticosteroid; IND, indacaterol; IPR, ipratropium bromide; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic receptor antagonist; LLB, levalbuterol; MDI, metered-dose inhaler; OLO, olodaterol; SABA, short-acting β2-agonist; SAL, salmeterol; SAMA, short-acting muscarinic receptor antagonist; SMI, soft mist inhaler; TIO, tiotropium; UME, umeclidinium; VIL, vilanterol.
The SAMA and SABA treatments above are indicated for rescue therapy in patients with COPD. The LAMA, LABA, LAMA/LABA and ICS/LABA treatments are indicated for the maintenance treatment of COPD. Ipratropium (Atrovent) and ipratropium/albuterol (Combivent and DuoNeb) may be used as both a maintenance and rescue therapy.
↵a Boehringer Ingelheim;
↵b Teva Respiratory;
↵c GlaxoSmithKline;
↵d Schering;
↵e Sunovion;
↵f AstraZeneca;
↵g Novartis;
↵h PARI International;
↵i Monaghan Medical Corporation;
↵j DeVilbiss Healthcare;
↵k Activaero GmbH;
↵l Mylan.
* One example of each nebulizer device type provided.
↵† Not yet approved for therapy in patients with COPD.